Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy

Noor Rizvi[1], Eliseos J. Mucaki[1,2], Emily L. Salmini[1], Monica Zhang[2], Sabina Trebinjac[3], Ezra Hahn[3], Lawrence Paszat[3], Sharon Nofech-Mozes[4], Michael T. Hallett[1,5,6], Eileen Rakovitch[3], Vanessa Dumeaux[1,2,5,6]

[1] Department of Biochemistry, Western University, London, Canada; [2] Department of Anatomy and Cell Biology, Western University, London, Canada; [3] Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; [4] Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; [5] Department of Oncology, Lawson Research Institute, London Health Sciences Centre, London, Canada; [6] Centre for Translational Cancer Research, Western University, London, Canada.

Corresponding author: Vanessa Dumeaux (vdumeaux@uwo.ca)

Abstract

Background

Managing Ductal Carcinoma in Situ (DCIS) remains challenging due to the lack of reliable biomarkers to predict radiotherapy (RT) response, leading to both overtreatment of indolent disease and undertreatment of aggressive cases.

Results

Through whole-exome sequencing of 147 DCIS cases, we characterized the genomic landscape of pure DCIS and identified genetic alterations associated with the risk of recurrence, either in-situ or invasive. DCIS lesions harbored frequent mutations in established cancer drivers (*PIK3CA*, *TP53*) and genes regulating tissue architecture, which likely enhanced pre-invasive cell fitness but lacked prognostic value. A subset of younger patients exhibited distinct mutational processes characterized by high mutational burden, though these were not linked to recurrence risk. Across the cohort, five mostly mutually exclusive genes (*SH2B2*, *PDZD8*, *MYO7A*, *MUCL3*, *DNASE2B*), involved in cell adhesion, membrane organization, and DNA degradation, were significantly associated with 10-year risk of local recurrence. In RT-treated patients, we identified 27 additional mutated genes uniquely associated with recurrence, along with *SH2B2* and *MUCL3*. Most of these genes were involved in cytoskeletal regulation, cell adhesion, and cell-environment interactions. Mutations in metabolic regulators (*MGAM2* and *AADACL3*) and *REV1*, which mediates DNA damage tolerance, may impair cellular responses to RT-induced stress. Notably, we identified distinct genes prognostic for in-situ versus invasive recurrence: nineteen genes predominantly involved in tissue structural maintenance in in-situ relapse, and thirteen genes primarily affecting cell-cycle and genome-

stability pathways in invasive progression. Copy number analyses revealed that pure DCIS

exhibits molecular subtype-specific patterns characteristic of invasive disease, with novel

alterations associated with recurrence, including three non-adjacent gains and five losses in

regions harboring oncogenes, tumor suppressor genes, and genes regulating structural

integrity, cell-cell adhesion and interactions.

Conclusions

While *TP53*, *PIK3CA*, and recurrent copy number alterations represent early events in

tumorigenesis, they lack prognostic value in pure DCIS, underscoring the need for alternative

biomarkers. Our findings identify key genetic alterations associated with local recurrence and

RT resistance. We further uncovered distinct molecular programs underlying in-situ versus

invasive recurrence, with mutations affecting tissue structural maintenance in in-situ relapse

and cell-cycle/genome-stability pathways in invasive progression.

Introduction

Ductal Carcinoma in Situ (DCIS) is a non-invasive, non-obligate precursor of invasive breast

cancer characterized by clonal proliferation of neoplastic cells confined within the breast ducts

[1]. DCIS is primarily detected through screening and diagnostic mammograms due to its

characteristic presentation with microcalcifications. The widespread implementation of

mammographic screening programs has led to a substantial increase in DCIS detection, with

incidence rates rising from four to eleven cases per 100,000 women between 1993 and 2007

[2,3]. This trend is expected to continue as screening programs expand to include younger

women [4].

There are currently no definitive markers to predict which cases will progress to invasive, life-

threatening lesions [5,6]. Consequently, treatment, usually involving breast-conserving surgery

(BCS) followed by breast radiation therapy (RT), is recommended for all women diagnosed

with DCIS [5]. However, many DCIS would not transit to invasive life-threatening disease even if

left untreated [7]. The absence of known markers predictive of a patient benefit to RT results in

both over-treatment for indolent lesions and under-treatment for some aggressive DCIS likely

to evolve to an invasive state. Markers that identify such cases could enable tailored

treatments, such as full mastectomy or adjuvant systemic therapies for patients at risk of in

situ or invasive local recurrence (LR) despite receiving RT [8], or more frequent watch-and-wait

strategies for those with indolent lesions.

Cancer emerges from the accumulation of genetic aberrations in neoplastic cells and genomic

instability [9]. Mutations can disrupt normal cellular processes, leading to uncontrolled cell

growth, impaired DNA repair, and other aberrant cellular behaviours that may contribute to

cancer development [9]. Previous studies have revealed important insights into DCIS

progression by highlighting specific mutations and chromosomal alterations that may

influence the progression towards invasive disease [10–17]. Many of these studies, however,

focus on synchronous DCIS – concurrent presentation of DCIS and invasive ductal carcinoma

(IDC). These studies explore the overlap between DCIS and IDC, and recognize the potential

differences between them. However, these findings might be reflective of a timepoint beyond

the evolutionary bottleneck, and the full repertoire of mediators of the transition from DCIS to

IDC or associated with a future risk of LR cannot be established from these studies [10].

TP53 and *PIK3CA* [11−17] are among the most frequently observed mutations in these studies

[11−17] and are often characterized as key drivers of tumorigenesis, promoting growth and

spread of cancer cells. However, this may not necessarily be the case, as mutant field

clonalization could equip pre-malignant cells with additional (epi-) genetic mutations that

confer fitness advantages, allowing them to expand into ductal regions without directly driving

invasive behavior [10]. This suggests that driver mutations, alongside frequently mutated

genes, may serve as these early fitness enhancers rather than drivers of progression. Several

copy number aberrations (CNAs) have also been identified by these studies [10−15,17−20]

including frequent gains at 1q, 8q, 11q, and 17q, and losses at 16q, however the specific

associations of these CNAs to DCIS prognosis remain unclear.

To address these critical gaps, we conducted comprehensive exome sequencing analysis of

147 pure DCIS cases, including patients treated with and without RT, to investigate markers of

local recurrence within 10 years of diagnosis. Our study characterizes the mutational

landscape in pure DCIS and identifies novel genomic alterations associated with tumor grade,

molecular subtypes, and patient age. Most importantly, we discovered specific variants and

CNAs predictive of local recurrence risk, including genetic markers associated with RT

response. These findings provide insights into the genomic determinants of DCIS prognosis

and treatment response, establishing a foundation for improved risk stratification and

personalized treatment strategies for DCIS patients.

Results

A unique cohort of pure DCIS patients

We assembled a cohort of 147 pure DCIS patients treated with BCS, with or without subsequent RT, incorporating comprehensive genomic profiling through whole-exome DNA analysis of primary DCIS tumors and matched normal tissues (**Table 1**). The study design was balanced to include at least a third of patients who experienced an ipsilateral invasive or in-situ local recurrence within a 10-year follow-up period and about half received radiotherapy as part of their standard-of-care (**Table 1**). In clinical settings, RT is omitted in some patients with low-risk features of DCIS or due to patient preference. The median time to recurrence was 4.2 years for invasive disease and 2.1 years for in-situ disease. Most tumors were of intermediate to high grade spanning all five molecular subtypes, with normal-like and luminal A subtypes more frequently observed in patients without local recurrence within 10 years (**Table 1**). A minority of tumors exhibited multifocality (24.5%) and positive margins (6.8%). Clinical characteristics were comparable between RT-treated and untreated patients across all variables except age, with women aged 60 years or older less likely to receive RT (**Supplementary Table 1**).

		Without Local Recurrence (n = 96)	With Local Recurrence (n = 51)	p-value[a]
Type of 10-year Local Recurrence	DCIS	0	24 (47.0%)	
	Invasive	0	27 (53.0%)	
Time to Recurrence in years Median (Range)	DCIS	NA	2.1 (0.5 – 9.7)	
	Invasive	NA	4.2 (0.6 – 9.7)	

Radiotherapy (RT) N (%)	Yes	51 (53.1%)	22 (43.1%)	0.32
	No	45 (46.9%)	29 (56.9%)	
Clear Margins N (%)	Positive	5 (5.2%)	5 (9.8%)	0.57
	Negative	79 (82.3%)	40 (78.4%)	
	Undetermined	12 (12.5%)	6 (11.8%)	
Tumor size (mm), Median (Range)		16.3 (4.0 - 90.0)	21.3 (2.0 - 76.0)	0.05
Nuclear Grade N (%)	Low	2 (2.1%)	2 (3.9%)	0.31
	Moderate	61 (63.5%)	26 (51.0%)	
	High	33 (34.4%)	23 (45.1%)	
Multifocality N (%)	Present	19 (19.8%)	17 (33.3%)	0.14
	Absent	48 (50.0%)	24 (47.1%)	
	Undetermined	29 (30.2%)	10 (19.6%)	
Age N (%)	<50 Years Old	37 (38.5%)	15 (29.4%)	0.11
	50-60 Years Old	34 (35.4%)	14 (27.5%)	
	>60 Years Old	25 (26.1%)	22 (43.1%)	
PAM50 Subtype (Pearson Correction) N (%)	Basal-like	12 (12.5%)	9 (17.6%)	0.01
	Her2-like	9 (9.4%)	9 (17.6%)	
	LumA	27 (28.1%)	5 (9.8%)	
	LumB	9 (9.4%)	12 (23.5%)	
	Normal-Like	20 (20.8%)	5 (9.8%)	
	Undetermined	19 (19.8%)	11 (21.6%)	

120   [a] Chi-square and t-test statistics for categorical and quantitative variables, respectively

121   **Table 1. Patient and tumor clinical attributes**

Mutational landscape of DCIS reveals distinct processes driving high mutational burden in

early-onset cases

The mutational load of pure DCIS lesions varied considerably, ranging from. 3 to 3,482 non-synonymous variants per sample (median 75) The majority (74.2%) were missense mutations, constituting approximately 52K unique variants identified in ~14K genes. Most of these genes were not frequently mutated, with 2,030 genes (14.5%) harboring non-synonymous aberrations in at least 5 patients.

As expected, most mutations are of C>T type (barplot in **Fig. 1**), a common mutational pattern attributed to the spontaneous deamination of 5-methylcytosine, a process frequently observed in many cancer genomes [21,22]. Spontaneous deamination can be exacerbated in FFPE samples due to DNA damage [23]. FFPE-related mutational artefacts are known to resemble certain COSMIC signatures [24], such as SBS30 and SBS1 [25]. During library preparation, formalin-induced DNA lesions are chemically repaired with unrepaired profiles resembling SBS30 and repaired profiles resembling SBS1 [25]. While SBS30 was not identified in our dataset, SBS1 was detected in a large number of samples (**Fig. 1**). SBS1, commonly found in tumor genomes, is difficult to distinguish from repaired FFPE-related artifacts due to their high similarity [22,25]. However, previous research has demonstrated that mutational profiles from repaired FFPE samples closely match true tumor mutational profiles [25], and we expect that our careful processing of mutation calling-pipeline minimizes the impact of these artefacts [23].

Interestingly, a subset of DCIS samples exhibit a significantly higher tumor mutational burden (TMB), characterized by an increase in frequency of C>G, T>C, and C>A mutations, and

enrichment of specific SBS signatures including SBS26, SBS7b, and SBS5 (**Fig. 1**, 12 samples

on the right). The causes underlying these mutational signatures remain incompletely

understood. However, SBS26 has been linked to impaired mismatch repair and microsatellite

instability. These cases were not more likely to have a recurrence, of a higher grade or of a

specific molecular subtype but were predominantly found in younger patients (8 out of 12

under 50 years; Chi-square test p-value < 0.05).

These findings highlight distinct mutational processes in some early-onset DCIS cases, though

these molecular features were not associated with prognosis.

Fig. 1: Mutational Signatures in pure DCIS samples.

The top panel shows tumor mutational burden (TMB) with distribution of point mutation types.

Clinical annotations display 10-year local recurrence outcome, tumor grade, molecular

subtype, and patient age. The bottom heatmap depicts the row-scaled relative contribution of

single base substitution (SBS) signatures detected in at least 10 samples (z-score). Samples

(columns) and signatures (rows) are ordered based on a rank-sum statistic that maximizes the

coherence of contribution patterns. The method first splits signatures into two groups using

medoid clustering. For each signature, relative contributions are ranked within each group, and

the final sample ordering is determined by the average rank-sum across all signatures.

Pure DCIS is associated with high frequency of mutations in genes involved cell adhesion,

polarity, tissue structure and function

Analysis of pure DCIS revealed distinct patterns of recurrent mutations across multiple genes

(**Fig. 2**). *PIK3CA* was the most frequently mutated gene (15% of cases), followed by *FSIP2* and

KIR3DL3 (14%). We also identified functional gene groups among the most frequently mutated

genes including several motor genes converting chemical energy to mechanical force

(*DNAH12, DNHD1*, and *MYOB15;* 12% each), collagen genes (*COL18A1* and *COL4A3*; 12%

and 10%, respectively), and mucin genes (*MUC3A, MUC4, MUC22*, and *MUC5AC)* also showed

alterations (10-12% of cases each). While mucin genes are typically large and can accumulate

mutations by chance, these specific mucin genes were not identified as FLAGS (FrequentLy

mutAted GeneS) and therefore not excluded in our analysis (See Methods). Given our stringent

rules for mutation calling, these findings suggest that mutations in mucin and other genes

controlling epithelial-components including cellular morphology, epithelial function and

adhesion are central to the physiopathology of pure DCIS.

We also identified a few mutated genes enriched in distinct clinico-pathological groups

including patients with early-onset DCIS (*FILP1L, CFAP61, FREM1*) or later-onset (*ERBB4*), high-

grade lesions (*TP53*) and Her2-enriched subtype (*ASH1L, NAGPA, DMD*) (**Figure 2B**).

Collectively, these findings highlight that pure DCIS harbors frequent mutations in genes

governing tissue architecture and cell-cell interactions, suggesting these alterations may be

fundamental to DCIS development.

Fig. 2: The most frequently mutated genes and association with clinico-pathological

variables in pure DCIS patients.

a The top 50 most frequent non-synonymous small variants identified in pure DCIS lesions.

Samples are in columns and variants are color-coded based on their classification. The TMB

for each lesion is displayed at the top of the heatmap. Samples are organized by age at

diagnosis, with additional clinico-pathological features—grade and subtype—depicted at the

bottom. **b** Mutated genes significantly associated with specific clinico-pathological variables

(False discovery rate [FDR] < 0.001). The barplots show the proportion of mutated samples

within specific categories: age group (left), high grade (middle), and Her2-subtype (right).

Proportions for each category are compared to the proportions of mutated samples in the

other respective groups (shown in grey).

Established cancer driver genes are present in pure DCIS but lack prognostic capacity

To identify potential cancer driver genes, we analyzed the ratio of non-synonymous to

synonymous mutations (dN/dS) across all genes, which can indicate positive selection of

mutations that provide growth advantages to cancer cells [26]. This analysis identified two

significantly mutated driver genes in pure DCIS: *PIK3CA* and *TP53* (FDR < 0.05). Both genes

were also among the most frequently mutated genes (**Fig. 2a**, red-labelled genes). While

PIK3CA mutations were not enriched in specific molecular subtypes, TP53 mutations were

significantly more frequent in basal-like and HER2-enriched subtypes compared to other

subtypes (19% in basal-like [4/21], 33% in HER2-enriched [6/18] vs 5% in other subtypes [4/78],

Chi-square test p < 0.005).

Out of 34 samples carrying a mutation in at least one of these driver genes, 15 samples

harbored at least one potentially actionable alteration as indicated by OncoKB (**Supplementary**

Fig. 1). The mutation spectrum in *PIK3CA* was dominated by the activating H1047R hotspot

mutation (~50%) in the kinase domain of exon 21, known to enhance PI3K-mitigated pathway

signaling (**Supplementary Fig. 1a**) [27,28]. Similarly, *TP53* mutations clustered in known

hotspots within the DNA-binding domain, which may result in the loss of tumor suppression by

affecting its ability to bind to DNA (**Supplementary Fig. 1b**).

Despite their established roles in cancer progression, none of these driver mutations was

associated with 10-year local recurrence risk (Firth's penalized likelihood Cox regression p >

0.5), suggesting that additional factors influence DCIS prognosis.

Identification of mutations associated with increased local recurrence risk independent of

treatment

To identify potential prognostic markers, we analyzed mutated genes associated with the risk

of invasive or in-situ local recurrence in the ipsilateral breast occurring between 6 months and

10 years after diagnosis. Our survival analysis identified five biomarkers each significantly

associated with increased 10-year local recurrence risk (Firth's penalized likelihood Cox

regression p-value < 0.01 & permuted p-value < 0.05; **Fig. 3a-b**). These mutations, occurring in

4-7% of cases, were largely mutually exclusive and occurred across molecular subtypes and

grades.

The presence of mutations in at least one of these genes was significantly associated with

increased recurrence risk (**Fig. 3c,** log-rank p-value p<0.0001), with *MYO7A* and *PDZD8*

showing the strongest associations (Firth's penalized likelihood Cox regression HR>4.4, **Fig.**

3b). Gene Ontology analysis revealed that most genes are involved in multiple interrelated

cellular processes including cell adhesion (*MYO7A*, *SH2B2*), organization and function of the

cellular membrane (*PDZD8*, *MUCL3*, *MYO7A*), and cellular organization and cytoskeleton

(*MYO7A*, *PDZD8*) (**Fig. 3d**). Additionally, *DNASE2B*, a member of the DNase II family of

endonucleases, was identified among the significant genes. These findings underscore how

cytoskeletal reorganization, changes in cell structure, and compromised cell adhesion might

contribute to increased risk of recurrence within 10 years after a DCIS diagnosis.

Fig. 3: Gene variants associated with an increased 10-year local recurrence risk in DCIS.

a Samples are in columns and variants are color-coded based on their classification. Local

recurrence status and clinico-pathological characteristics of each lesion are depicted at the

bottom. Local recurrence is defined as any recurrence, in situ or invasive, in the ipsilateral

breast occurring between 6 months and 10 years after diagnosis. Right-hand side reports the

proportion of each variant classification type. **b** Hazard ratio and confidence intervals for each

significant mutated gene associated with increased 10-year local recurrence risk (Firth's

penalized likelihood Cox regression). **c** Kaplan-Meier analysis of local recurrence-free survival

(LRFS) comparing patients with mutations in at least one of the 5 genes (red) versus those

without mutations (blue). **d** Cellular component Gene Ontology (GO) terms annotations for

each significant gene.

Mutations in genes governing cytoskeletal organization and membrane dynamics associated

with radiotherapy resistance

To identify predictive biomarkers for RT response, we analyzed mutations associated with 10-

year local recurrence in a cohort restricted to patients who received RT. This analysis revealed

29 genes significantly associated with an increased risk of recurrence (Firth's penalized

likelihood Cox regression p-value < 0.05 & permuted p-value < 0.05; **Fig. 4a**). Notably, these

mutations often co-occurred, with at least two mutated genes present in approximately 27% of

lesions (20/73 patients treated with RT).

In RT-treated patients, lesions harboring mutations in at least two of these genes exhibited a

markedly increased risk of local recurrence (Firth's penalized likelihood Cox regression HR =

4.8, 95% CI: 2.1–11.2, p = 0.0002), with most mutation-positive recurrences occurring within 5

years post-RT (**Fig. 4b**). Notably, while mutations in *SH2B2* and *MUCL3* were significantly

associated with prognosis in both the overall cohort and the RT-treated subgroup, an RT-

stratified analysis revealed that lesions harboring two mutations in the remaining 26 genes

(which were altered in at least five lesions in the no-RT group) were predictive of prognosis

only in RT-treated patients ($p < 0.0001$) and not in those who did not receive RT ($p > 0.5$)

(**Supplementary Fig. 2**).

Fig. 4: Mutations associated with radiotherapy resistance in DCIS.

a An oncoplot showing the distribution of mutations in 29 genes significantly associated with

local recurrence in RT-treated patients. Color-coding indicates mutation types; clinical

annotations show age, grade, molecular subtype, and 10-year recurrence status. **b** Kaplan-

Meier analysis of LRFS comparing patients with mutations in at least two of the 29 genes (red)

versus those without mutations (blue). **c** Distribution of TMB, shown as number of non-

synonymous variants, log2 scale) for lesions with at least one mutation in two genes

associated with LRFS colored by recurrence status at 10 years. **d** GO cellular component

enrichment network analysis of recurrence-associated genes in RT-treated DCIS. Network

visualization shows enriched GO terms (FDR < 0.2) from genes linked to local recurrence

following RT. Nodes represent individual GO terms with size proportional to gene count (>2),

and edges indicate significant semantic similarity between terms. Node color intensity

corresponds to enrichment significance.

Given the frequent co-occurrence of these mutations, we assessed whether overall TMB might

explain the increased recurrence risk. Although several high-TMB lesions were observed

among patients with these mutations (**Fig. 4a,c**), TMB itself was not significantly associated

with local recurrence risk (Firth's penalized likelihood Cox regression p = 0.8). Indeed, many

lesions with high TMB remained recurrence-free over 10 years, suggesting that specific

mutations—not overall mutation load—drive LR after RT. We further examined potential

confounding by clinico-pathological variables (i.e. age, grade, tumor size, multifocality and

subtype) by adjusting our survival model for each factor. The predictive value of these

mutations remained significant (Firth's penalized likelihood Cox regression p-values < 0.005),

supporting their role as an independent risk factor for recurrence following RT.

Functional analysis revealed a network of interrelated cellular functions involved in actin

cytoskeleton regulation, cellular polarity, and membrane dynamics—processes essential for

invasive behavior (**Fig. 4d**).

Alterations in *SH2B2* and *SORBS1*, which modulate stress fiber formation and actin

remodeling, and in *PTPN13* and *WWC1*, which affect actomyosin tension at the cell leading

edge, suggest disruptions in cytoskeletal dynamics. Additional genes associated with

prognosis in RT-treated include *KRT1, MUCL3, TMEM132C, TTLL10, EML5, CEP128, CFAP47,*

and *KIF24*, all of which contribute to maintaining cellular architecture, polarity, and adhesion

(**Fig. 4a**). In addition, alterations in metabolic regulators—such as *MGAM2* and *AADACL3*—

could influence the energetic and biosynthetic demands required in response to RT-induced

stress, while *REV1* is implicated in DNA damage tolerance, a critical safeguard following

genotoxic stress.

Collectively, these findings highlight the pivotal roles of cytoskeletal reorganization, membrane

remodeling, metabolic regulation, and DNA repair pathways in the response to RT. The

prognostic significance of these mutations in RT-treated patients suggests that these gene

alterations may mediate resistance mechanisms triggered by RT-induced stress.

Differential mutational associations with in-situ versus invasive local recurrence after

radiotherapy

To investigate whether individual mutations are preferentially linked to either in-situ or invasive

LR, we refitted the gene-based survival models using each LR type as the sole endpoint (the

alternative event was censored) and stratified the analyses by RT. For the full cohort we had

retained genes with $p < 0.01$ and permutation $p < 0.05$; for the smaller RT-treated group we

used $p < 0.05$ and permutation $p < 0.05$. As in the main analysis, many significant associations

were found in RT-treated patients, with some overlap with significant genes found in the whole

cohort (**Fig. 5a**).

Three genes—*MUCL3*, *SH2B2* and *C6orf118*—were associated with outcome in at least three

out of six analyses (**Fig. 5a**). In RT-treated tumours, fifteen genes were associated with in-situ

LR or with "any LR", and two genes (*CFAP47*, *KRT1*) were associated with invasive or with "any

LR" (**Fig. 5a**). Nineteen additional genes were uniquely associated with in-situ LR (**Fig. 5b**),

whereas thirteen were unique to invasive LR (**Fig. 5c**) within the RT subgroup. The Kaplan-

Meyer analyses demonstrate that patients whose lesions harbor mutations in at least two

genes from either the in-situ-specific or invasive-specific gene sets show significantly worse

LR-free survival only for the corresponding recurrence type (**Fig. 5d,e**).

Fig. 5: Differential mutational associations with in-situ versus invasive local recurrence after radiotherapy

a An UpSet plot showing the number of genes significantly associated with risk of invasive, in-situ or any local recurrence (LR) in the whole cohort (all) and in RT-treated (RT) or untreated patients (noRT), with intersections between gene lists indicated by connected dots below and corresponding size of the intersection depicted in the barplot on the right. **b** Oncoplot showing mutations in genes uniquely associated with in-situ LR (n=19) in RT-treated patients. Color-coding indicates mutation types; clinical annotations show age, grade, molecular subtype, and

recurrence status. **c** Similar to b but showing mutations in genes uniquely associated with

invasive LR (n=13) in RT-treated patients. **d** Kaplan-Meier analysis of in-situ (left) or invasive

(right) LR-free survival comparing patients with mutations in at least two of the 19 genes

uniquely associated with in-situ LR (red) versus those without mutations (blue). **e** Similar to d

but comparing in-situ or invasive LR-free survival between patients with mutations in at least

two of the 13 genes uniquely associated with invasive LR versus those without mutations.

Functional annotation indicates that mutations uniquely linked to in-situ LR occur mainly in

genes that preserve epithelial architecture and mechanosensing: anchoring-junction

components that couple cells to neighbouring cells or to the extracellular matrix (*DMD*,

FOCAD), the stretch-activated channel *PIEZO1*, and scaffolds/adaptors localised to actin-rich

membrane projections such as invadopodia (*SHANK3*, *PRAG1*). The set also includes WDFY4, a

WD-repeat/FYVE-domain autophagy adaptor implicated in MHC-II antigen presentation.

Conversely, mutations associated with invasive LR after RT mapped to genes involved in late

cytokinetic abscission (*PDCD6IP*), centriole-to-centrosome maturation (*CEP295*), DNA-damage

sensing and repair (*SETX*, *TNKS1BP1*), calcium-regulated motility (*CACNA1I*) and cytokine-

dependent inflammatory signalling (*TYK2*).

Because stratifying simultaneously by treatment and LR type reduces sample size and event

numbers, we cannot exclude the possibility that some endpoint-specific associations—or the

absence of others—reflect differences in statistical power. Nevertheless, these findings

suggest that distinct biological programs—structural maintenance versus cell-cycle, genome-

stability and inflammatory pathways—underlie in-situ and invasive patterns of recurrence after

RT.

Copy number alterations display molecular subtype-specific patterns with select genomic

regions linked to local recurrence

Analysis of copy number alterations (CNAs) revealed recurrent chromosomal changes similar

to those reported in invasive breast cancer (**Fig. 6a**). Significant gains were identified on

chromosomal arms 1q, 8q, 16p, 17q, 20p, and 20q, while losses predominantly occurred on 8p,

9p, 11q, 13q, 14q, 16q, and 17p (binomial test, FDR < 0.05).

Global CNA burden varied considerably across samples, with approximately half showing

minimal alterations (global CNA score < -0.58; **Fig. 6b**). Basal-like tumors exhibited greater

CNA burden, while normal-like tumors showed fewer alterations (**Fig. 6b**, **Supplementary Fig.**

2a). Similarly, high-grade lesions showed a greater CNA burden compared to low-grade lesions

(**Supplementary Fig. 3b**).

We identified distinct CNA patterns across molecular subtypes: basal-like tumors showed

enrichment for gains on 8q, 13q, and 19q; LumA tumors frequently exhibited 16q loss; and

Her2-enriched tumors showed characteristic 17q12 gains corresponding to the *ERBB2* locus

(Fisher's exact test, p < 0.005; **Supplementary Fig. 3c**).

Fig. 6: Frequent copy number alterations in pure DCIS and associations with 10-year LR risk

a Genome-wide frequency of absolute copy number gains and losses across chromosomes 1-

22 (1Mb window). The estimated ploidy for each sample is subtracted from the copy number

values of each segment which means that a copy number of 0 is no copy number change. The

y-axis shows the percentage of samples with each alteration type. Asterisks indicate statistical

significance for chromosomal arm alterations **b** Heatmap showing copy number profiles per

cytoband across samples (rows), ordered by global CNA score (GCS). Sample annotations

include age, grade, molecular subtype and local recurrence status at 10 years. **c** Heatmap of

twenty genomic regions significantly associated with 10-year risk of local recurrence (Firth-

corrected cox model p-value < 0.05 adjusted for grade), showing copy number status. CNAs

present in at least 5 patients are shown, with copy number gains in red and losses in blue.

Samples and regions were clustered using Ward's hierarchical clustering with Minkowski

distance metric.

Fourteen cytoband regions were significantly associated with increased 10-year local

recurrence risk after grade adjustment (Firth's penalized likelihood Cox regression p-value &

permuted p-values < 0.05; **Fig. 6c**). These included copy number losses in five non-adjacent

cytobands and gains in three non-adjacent cytobands. When analyzing invasive local

recurrence specifically, four regions were shared (losses in 5q32-33, 9p21, 18p11), with two

additional losses identified in 9p13 and 8q11 and one gain in 5p15 (Firth's penalized likelihood

Cox regression p-value < 0.01 & permuted p-value < 0.05).

Copy number losses could alter critical tumor suppressor functions, as evidenced by the

presence of several well-known tumor suppressor genes within these regions. Notable

examples include *CDKN2A* at 9p21 (a key regulator of cell cycle progression), *PRDM4* at

12q23-24 (involved in cell differentiation and tumorigenesis) [29], *SPARC* at 5q33 (important

for extracellular matrix synthesis and modulation of cell shape) [30] and MITOSTATIN at

12q24 (a mitochondrial protein with tumor suppressor activity) [31]. Additional loss highlights

disruptions in cell adhesion and intercellular contacts as loss of 18p11 may affect DAL-1, a

known regulator of cell adhesion and link between cell membrane and cytoskeleton [32,33].

Gains were identified in regions harboring oncogenes or potential cancer-related genes. For

example, amplification in the 11q region—including 11q13, which contains *CCND1* and *CTTN*—

previously associated with breast cancer aggressiveness [34,35]. Additionally, a gain in 5p14

includes four cadherin genes (*CDH10, CDH9, CDH12, CDH18*) and *PRDM9*, whose aberrant

expression has been associated with genomic instability [36].

Collectively, these findings demonstrate that the CNAs associated with 10-year local

recurrence not only affect regions harboring established tumor suppressors and oncogenes

but also target regions involved in cell structural integrity and cell-cell interactions, potentially

contributing to an aggressive and treatment-resistant phenotype.

Contextualizing our genomic findings with prior profiling studies: consistent early mutational

drivers, novel subtype-specific CNA patterns, and predictors of RT response

Most prior DCIS genomic studies analyzed small cohorts (<100 cases) and primarily focused

on DCIS cases with concurrent invasive disease (synchronous DCIS) rather than pure DCIS

(**Supplementary Table 2**). While recent larger studies, such as those by Strand *et al.* (2022) [20]

and Kader et al. (2024) [37], examined hundreds of pure DCIS cases, their reliance on low-pass

sequencing or lack of matched normal tissues limits the sensitivity for detecting genomic

changes, particularly when working with FFPE samples, which are often the only available

option for DCIS studies.

Across studies, *PIK3CA* and *TP53* consistently emerged as the most frequently mutated genes

in DCIS (and invasive disease), with mutation rates ranging from 21−55% and 17−52%,

respectively (**Supplementary Tables 2-3**). In our cohort, *PIK3CA* and *TP53* were also among

the most frequently mutated genes and identified as tumorigenesis drivers in pure DCIS.

Mutations in *GATA3* and *ERBB2,* which were frequently reported in several studies, were only

detected in a small number of lesions in our cohort (n = 3 and 7, respectively, **Supplementary**

Table 3). Overall, we observe very little overlap between genes reported as frequently mutated

across studies (**Supplementary Table 3**). Differences across studies likely reflect variations in

methodology, including variant-calling pipelines, sample types (e.g., synchronous vs. pure

DCIS), cohort composition (e.g., histological grade and ER/HER2 status), and our study's

specific focus on LR and RT response, complicating direct comparisons. Nevertheless, the

consistent identification of *PIK3CA* and *TP53* as the most frequently mutated genes across

studies and in our cohort reinforces their pivotal roles in the early stages of breast

tumorigenesis.

Recurrent CNAs in regions such as 1q, 8q, and 17q gains, as well as 8p, 11q, and 16q losses,

were observed in our study, consistent with prior DCIS findings, including those from Strand *et*

al. (2022) [20] and Abba *et al.* (2015) [15]. For example, Strand *et al.* (2022) identified 29

recurrent CNAs in DCIS but found no single CNA predictive of recurrence [20]. In contrast, we

identified twenty genomic regions significantly associated with 10-year local recurrence risk,

including regions containing known tumor suppressors and oncogenes. These differences

may reflect the higher resolution of our sequencing approach (100x whole-exome sequencing)

compared to the low-pass sequencing used in prior studies. Our study also provides valuable

new insights into molecular subtype-specific CNA patterns in DCIS. In our cohort, basal-like

tumors exhibited gains on 8q, 13q, and 19q; Luminal A tumors displayed 16q loss; and Her2-

enriched tumors showed 17q12 gains encompassing *ERBB2*. Aside from amplifications in

HER2-positive subtypes, subtype-specific CNA analyses remain poorly represented in the DCIS

literature but are well established in invasive breast cancer (**see Supplementary Text**). These

findings suggest that genetic and molecular aberrations defining subtypes likely arise early

and are at least partially established at the DCIS stage.

Finally, while several studies have explored prognostic markers of recurrence, few account for

treatment variation, and none specifically examined markers of RT response (**Supplementary**

Table 2). Our study uniquely identified genetic alterations within a gene network that integrates

cytoskeletal integrity, cell-cell interactions, cell adhesion, and metabolism which are

associated with an increased risk of local recurrence within five years following RT. These

findings suggest that these alterations may play a critical role in resistance mechanisms

activated by RT-induced stress.

Discussion

Our study provides a comprehensive analysis of pure DCIS, focusing on DNA profiles

associated with disease prognosis and response to RT. While previous research has primarily

examined genomic changes in synchronous DCIS compared to IDC or pure DCIS, our work

offers a detailed view of the mutational landscape specific to pure DCIS and its association

with LR. Importantly, we identified genomic alterations associated with molecular subtypes

and, most critically, LR—both independent of treatment and specifically in cases following RT—

highlighting potential molecular drivers of treatment outcomes. We also observed distinct

mutational processes in early-onset DCIS with high tumor mutational burden potentially driven

by impaired mismatch repair, but these were not associated with prognosis.

While driver genes like *TP53* and *PIK3CA* are critical in the early stages of tumorigenesis, our

study did not find any significant associations between their mutations and disease

progression or response to treatment. These findings suggest that TP53 and PIK3CA

mutations are essential for overcoming initial biological constraints during early tumor

development but may become less relevant to progression once these barriers are surpassed.

This aligns with prior research showing that these mutations are frequently retained in invasive

carcinoma but occur at higher prevalence in hyperplastic and DCIS lesions [38].

Furthermore, their prognostic relevance appears to depend on tumor clinicopathological

characteristics. For example, Lin et al. [11] observed an inverse association between *PIK3CA*

kinase domain mutations in high-grade DCIS tumors and progression, while Silwal-Pandit et al.

[39] reported that the prognostic impact of *TP53* mutations varied across molecular subtypes

of invasive breast cancer. These findings underscore the complexity of breast cancer

progression, where early driver mutations interact with additional genetic and

microenvironmental factors to shape disease outcomes.

We identified recurrent CNAs frequently reported in the literature, including gains on 8q [10–

12,14,15,37,40], 17q [10,12,15,18–20,37,40], 20q [37,40], and losses on 11q [10–12,18,19,37]

and 16q [10,13,14,20,40]. These CNAs mirror those observed in invasive ductal carcinoma,

suggesting that pure DCIS already harbors genomic features characteristic of invasive

cancer—including alterations that define molecular subtypes (e.g., basal, luminal-A, or Her2-

enriched tumors; **see Supplementary Text**). Moreover, this observation is consistent with

earlier transcriptional and epigenetic studies that show subtype-specific alterations in gene

expression and DNA methylation are already evident in DCIS [41,42]. These findings suggest

that genetic and molecular aberrations defining subtypes likely emerge early - being at least

partially established at the DCIS stage - and support a model of subtype-specific progression

from DCIS to invasive breast cancer [41].

Importantly, our study also revealed novel associations between mutations in genes regulating

cytoskeletal integrity, cell membrane organization and function, cell-cell interactions, and cell

adhesion, and the risk of LR in pure DCIS. Across the cohort, five genes were significantly

associated with LR, underscoring their potential roles in tumor progression. These mutations

were not frequently co-occurring in the same patient, and involved genes maintaining cell

adhesion (*MYO7A*, *SH2B2*), organizing and supporting cellular organization, cytoskeleton and

membrane function (*PDZD8*, *MUCL3*, *MYO7A*). When the cohort was stratified by RT

administration, 27 unique genes - excluding *SH2B2* and *MUCL3* - were significantly associated

with increased LR risk in RT-treated patients. Many of these mutations were identified in genes

critical for maintaining cellular architecture, polarity, and adhesion, such as *KRT1*, *MUCL3*,

TMEM132C, *TTLL10*, *EML5*, *CEP128*, *CFAP47*, and *KIF24*, highlighting how disruptions in

structural integrity and epithelial cell organization may undermine the effectiveness of RT and

contribute to LR. In addition to structural changes, metabolic regulators like *MGAM2* and

AADACL3 may influence the energetic and biosynthetic demands required for cell survival and

adaptation under genotoxic conditions. Alterations in *REV1*, a key player in DNA damage

tolerance, underscore the importance of effective DNA repair mechanisms following RT. These

findings expand upon prior studies linking disruptions in tissue structure and cell adhesion to

DCIS progression [43–46], while providing novel insights into their specific roles in recurrence

following RT in pure DCIS.

Notably, our analysis also revealed distinct biological programs underlying in-situ versus

invasive recurrence following RT. Specifically, while some mutations in genes involved in

structural maintenance and mechanosensory pathways were uniquely associated with in-situ

relapse, invasive progression was characterized by alterations in cell-cycle regulation, genome

stability, and inflammatory signaling. Because stratifying by both treatment and LR type

reduced our statistical power, these molecular distinctions will require confirmation in larger

cohorts.

Finally, we uniquely identified losses in cytobands harboring established tumor suppressor

genes—such as *CDKN2A* in 9p21 and *PRDM4* in 12q23–24—as well as regions containing

genes crucial for cell adhesion and migration, including a cluster of keratin genes in 12q13–14

and *DAL-1* in 18p11. In parallel, gains in regions like 11q, which includes oncogenic drivers

such as *CCND1* and *CTTN*, suggest that oncogene amplification may further contribute to

tumor aggressiveness and ultimately patient prognosis. Gains at 5p14, containing cadherin

genes (*CDH10*, *CDH9*, *CDH12*, *CDH18*), again emphasize the importance of maintaining

epithelial integrity to prevent LR in pure DCIS patients.

Future studies are warranted to investigate how these mutations interact with other molecular

pathways and microenvironmental factors to elucidate their contribution to DCIS prognosis

and the adverse effects of RT. Such research could help identify strategies to mitigate

recurrence risk following RT and improve treatment outcomes [47–49].

Conclusions

Our findings uncover the genomic landscape of pure DCIS and highlight key factors that

contribute to LR and mediate the adverse effects of RT. While *TP53* and *PIK3CA* mutations

play important roles in early tumorigenesis, they do not predict recurrence, emphasizing the

need for alternative biomarkers. We identify distinct mutational processes and genetic

alterations that disrupt cytoskeletal integrity, cell-cell interactions and cell adhesion, potentially

destabilizing the epithelial tissue environment and contributing to recurrence, particularly

following RT-induced stress. Importantly, our data also suggest that in-situ and invasive

recurrences after RT may follow divergent molecular trajectories—mutations affecting

structural maintenance and mechanosensory pathways were specifically linked to in-situ

relapse, whereas alterations in cell-cycle regulation, genome stability, and inflammatory

signaling characterized invasive progression. These insights provide a foundation for

understanding the genetic basis of DCIS progression and identifying potential molecular

drivers of treatment resistance. Future research will be essential to translate these insights

into clinical practice, guiding the development of more targeted therapeutic approaches to

improve outcomes for patients with DCIS.

Methods

Methods

The Ontario DCIS cohort

The Ontario DCIS Cohort was established at the Sunnybrook Health Sciences Center (Toronto,

Canada) as a population-based sample of women diagnosed with pure DCIS defined as in situ

cancer without any invasive component between 1994 and 2003 [50–52]. All patients

underwent BCS, with a subset receiving subsequent RT as part of their standard-of-care.

Adjuvant endocrine therapy was administered to less than 15% of individuals, while none

received systemic chemotherapy or neoadjuvant endocrine therapy. The cohort features

comprehensive annotation of clinical annotation and expert pathology review. Previous studies

of this cohort have characterized outcomes based on clinical factors including age at

diagnosis, pathological features (tumor size and nuclear grade), and treatment modalities [53–

56].

Sample selection was prioritized to achieve balanced representation between RT-treated and

untreated patients, with equivalent distributions of individuals who did or did not develop an

invasive or in-situ ipsilateral recurrence within ten years. Tissue cores were obtained from

FFPE blocks, sampling DCIS tumors without microinvasion alongside adjacent normal and

stromal tissues. DNA and RNA were extracted using the Qiagen AllPrep FFPE DNA/RNA kit

(Qiagen). Samples yielding sufficient DNA quantities underwent library construction using the

Agilent SureSelect Human Exome library preparation kit and were sequenced on the

NovaSeq6000 platform (100bp paired-end, 100M reads/sample) at the Genome Quebec

Innovation Centre (Montreal, Canada). While high-quality sequencing data was obtained for

300 tumor tissues, downstream analyses focused on 147 samples with matched normal

profiles (144 normal tissue and 3 stroma non-epithelial samples).

Molecular subtypes were determined using RNA profiles available for a subset of patients (n =

122). Sequencing libraries were prepared using RNA Flex kit (Illumina). Raw reads were

processed using `TrimGalore` to remove adapters and low-quality reads [57], followed by

alignment to the human genome (Ensembl release v104) using `STAR` [58]. Reads counts were

mapped to genomic features using `Rsubread` R package [59] and gene counts were

normalized using the variance stabilizing transformation implemented in the `DESeq2` R

package [60]. PAM50 subtype classification was performed using the `genefu` R package [61]

with established centroids [62]. Specifically, normalized expression data of the 50 PAM50

genes were obtained using variance stabilizing transformation implemented in the `DESeq2` R

package [60] and compared to subtype-specific centroids using Pearson correlations. Each

sample was assigned to the molecular subtype with which it showed the highest correlation

coefficient.

Whole-exome sequencing data preprocessing

Raw reads were processed using Trimmomatic [63] (version 0.39) to remove adaptor

sequences and low-quality bases. Reads were trimmed to retain high-quality sequences,

applying quality thresholds of 10 at read ends and 20 within a 4-base sliding window. The

remaining paired reads were processed following the GATK4 best practices. Briefly, reads

were aligned to the human reference genome (GRCh38, GATK resource bundle) using the

Burrows-Wheeler Aligner (BWA) [64]. Post-alignment procedures included sorting, annotating

reads with read groups, and marking duplicate reads with Picard. Base quality score

recalibration was conducted using GATK4 tools. A recalibration table was generated with the

`BaseRecalibrator` function using known variant sites (dbSNP138 for SNPs and Mills and

1000 Genomes for indels), and recalibration was applied with `ApplyBQSR` to adjust base

quality scores and correct for systematic technical errors. The process focused on SureSelect

Human Exons v7 regions with a 100 bp padding. Finally, properly paired reads were extracted,

excluding secondary alignments and low-quality reads, with the resulting files indexed using

`Samtools` [65]. After filtration, samples had a mean coverage depth of 152X (range: 52-308X,

standard deviation: 42X).

Single nucleotide variant & indel calling

For variant calling, we used NeuSomatic [66], a deep learning approach that leverages both

tumor and matched normal sequence alignment information, alongside somatic mutation calls

from six different approaches: MuTect2, MuSE, VarDict, VarScan2, Strelka2, and

SomaticSniper [67–72]. This method was selected because of the low level of agreement

between callers in our data - the majority of mutations (88.7%) were identified by only one

caller (**Supplementary Fig. 4a**) - an observation consistent with previous studies [73–75]. The

number of mutations detected varied significantly across samples, with the minimum

identified in any single sample being 1,563 mutations, and the maximum reaching 283,247

mutations (**Supplementary Fig. 4a**).

Small-variant calling has become increasingly amenable to deep learning approaches, thanks

to the availability of extensive sequencing data and robust benchmarking datasets that cover

millions of variants across diverse genomic contexts [76]. A convolutional neural network

(CNN) architecture leverages information from sequencing reads and the reference genome in

the vicinity of each candidate variant to approximate complex, nonlinear functions, accurately

classifying loci as homozygous variant, heterozygous variant or homozygous reference (non-

variant) [66].

Best practices established using well-characterized somatic reference datasets from the

SEQC-II consortium demonstrated that NeuSomatic models achieve robust performance

across various sequencing technologies - including both fresh and FFPE DNA inputs - across a

range of tumor/normal purities and sequencing coverages, significantly outperforming

conventional approaches [73]. Accordingly, we used the ensemble extension of NeuSomatic.

This extension combines outputs from six individual variant callers by integrating features

from 93 channels and incorporates an additional 26 channels to capture alignment

information in a window of seven bases around the candidate mutation, resulting in a total of

119 input channels per candidate matrix. We used the recommended pre-trained model SEQC-

II (SEQC-WGS-Spike model), which was trained on 20 whole-genome sequencing replicate

pairs containing *in silico* somatic mutations with allele frequencies ranging from 1% to 100%

(with matched normals at both 95% and 100% purity, and sequencing coverage ranging from

~40x to 220x) using five variant callers used: MuTect2, Strelka2, MuSE, SomaticSniper,

VarDict. After mutation calling, the recommended post-processing was applied to resolve long

INDEL sequences and the final NeuSomatic predictions were used for all downstream

analyses.

We obtained comprehensive genomic information for each variant using the Ensembl Variant

Effect Predictor (VEP) [77]. This included the effects on gene and protein function, such as

consequence types and amino acid changes, variant frequencies in different populations,

impact on regulatory regions, and potential associations with diseases and phenotypes.

Following annotation with the Ensembl VEP, we used the `vcf2maf` tool to transform VEP-

annotated VCF files into the Mutation Annotation Format (MAF). This conversion ensures each

variant is uniquely associated with a single gene transcript or isoform, despite the potential for

a variant to impact multiple isoforms. Particularly in cases where variants could be classified

under different effects — such as a `Missense_Mutation` near a `Splice_Site` — the MAF

format forces a singular designation for each variant by leveraging VEP's determinations for

canonical isoforms.

We excluded 100 genes commonly mutated in public exome datasets (FLAGS) due to their

lower likelihood of disease association [78]. This decision stems from their longer coding

regions, which inherently increase mutation probability, and the presence of paralogs that

might offset functional loss these mutations could cause [78,79].

High-confidence variants (identified with a probability score of 0.7 or higher) consistently

showed higher allele frequencies compared to those categorized as low-quality (with scores

between 0.4 and 0.7) and rejected variants (with scores below 0.4) (**Supplementary Fig. 4B**).

To reduce potential false positives, we selected high-confidence variants with allele frequency

above 0.1. To further confirm that variants detected were not technical artifacts, we assessed

the relationship between tumor mutational burden and sequencing depth (**Supplementary Fig.**

5). The lack of correlation supports robust variant detection independent of coverage.

Mutation patterns and frequencies were visualized using the `oncoplot` function from the

`maftools` R package [80], which displays mutation types and frequencies across samples.

Mutational signatures

We performed mutational signature analysis using the COSMIC database of single-base

substitution (SBS) signatures [24]. First, the trinucleotide context of each single nucleotide

variant was characterized. We then used the `fit_to_signature` function in the

`MutationalPatterns` R package (version 3.19) [81] to find the linear combination of

COSMIC mutation signatures that most closely reconstructs the mutation spectra for each

sample by solving the nonnegative least-squares constraints problem. We used strict refit

where the signature with the lowest contribution is removed; refitting is repeated until the

cosine similarity between the original and reconstructed profile becomes more than

max_delta= 0.004). We selected signatures that contributed to the mutation spectrum of at

least 10 samples and plotted their relative contributions using the `pheatmap` R package [82].

Driver genes

To identify driver genes (i.e., genes under positive selection in cancer), we used the `dNdScv`

analysis method [26]. This approach is based on the evaluation of the ratio between

synonymous (silent) mutations and non-synonymous (missense) mutations in genes. A higher

ratio of non-synonymous to synonymous mutations in a gene indicates positive selection for

mutations that may confer a growth advantage to cancer cells, suggesting the potential role of

the gene as a driver in tumorigenesis.

The dNdScv method estimates the background mutation rate of each gene by combining local

information (synonymous mutations within the gene) with global information (variation of

mutation rates across genes). This approach controls for the sequence composition of genes

and accounts for mutational signatures, providing a more accurate estimation of the expected

neutral mutation rate. In particular, the dNdScv R package [83] implementation uses

trinucleotide context-dependent substitution matrices to mitigate common mutation biases

that can affect dN/dS calculations [26].

To visualize and analyze the distribution and nature of mutations in driver genes, we used

lollipop plots generated from the maftools R package [80] and annotation tracks from

cBioPortal [84]. These plots provide a representation of mutation types and their locations

along the protein sequence as well as annotations including likely mutation hotspots as

identified by Memorial Sloan Kettering Cancer Hotspots and 3D Hotspots databases [85], and

annotation records of therapeutic indication from OncoKB [86].

Copy Number Alterations (CNAs)

To investigate copy number alterations, we applied the Allele-Specific Copy Number Analysis

of Tumours (ASCAT v3) on our tumor normal pairs estimating tumor purity, ploidy, and allele-

specific copy number [87]. The runAscat function was executed with default settings

optimized for high-throughput exome sequencing data, with the gamma parameter set to 1.

After examination of ASCAT sunrise plots, we identified a subset of samples (n=35 samples),

for which the initial estimates of tumor purity and ploidy did not align with the regions of

highest confidence on the sunrise plots. The runAscat was re-run for these samples by

manually assigning the aberrant cell fraction (tumor purity) and tumor ploidy parameters

corresponding to the regions of highest probability as depicted on the sunrise plots. Overall,

eight samples were excluded from further analysis due to poor goodness of fit leaving 139

samples with CNA profiles for downstream analyses. Absolute number gains and losses

shared across samples were visualized across whole chromosomal regions using aCNViewer

[88] (window size of 1 Mbp). The estimated ploidy for each sample is subtracted from the copy

number values of each segment which means that a copy number of 0 is copy number change.

These adjusted windows at base resolution are then plotted into a stacked histogram

representing genome-wide absolute copy number and copy neutral variations over all samples

in a group.

We applied a re-segmentation approach to adjust for amplitude divergence due to technical

variability implemented in CNApp [89] using the default settings (minimum segment length =

100 Kbp, minimum amplitude deviation from segment to zero = 0.16, maximum distance

between segments=1 Mb, maximum amplitude deviation between segments = 0.16, and

maximum BAF deviation between segments = 0.1). Re-segmented data were then used to

calculate the broad, focal and global CNA scores. We then transformed re-segmented data

into genomic regions profiles (chromosome arms, cytobands and sub-cytobands) using both

focal and broad segments. Length-relative means are computed for each window by

considering amplitude values from those segments included in each specific window. Default

cutoffs for low-level copy number gains and losses (i.e., |0.2|) were used to infer CNA

frequencies.

Survival analyses

We evaluated the association between gene mutations or copy number aberrations in

cytobands and 10-year local recurrence-free survival using Firth's penalized likelihood Cox

regression which accounts for small sample sizes and rare events. This analysis was

conducted using the `coxphf` R package [90]. Aberrations were included in the analysis only if

detected in at least five lesions (2,030 genes; 303 cytobands). This analysis was performed

across the entire patient cohort. To further investigate mutated genes associated with

response to RT, a stratified analysis was conducted based on treatment groups.

To control for multiple testing in the identification of mutated genes associated with LR, we

employed permutation-based testing (1,000 permutations) to establish empirical significance

thresholds. We required both a traditional p-value threshold ($p < 0.01$ for full-cohort analyses; p

< 0.05 for RT-stratified analyses) and a permuted p-value < 0.05.

Kaplan-Meier survival curves were used to visualize the results, illustrating event-free survival

probabilities over time for patients stratified by mutational status in the specified genes or

gene sets.

GO enrichment analyses were performed using the clusterProfiler R package [91]. Entrez gene

identifiers were mapped to GO terms using the `org.Hs.eg.db` annotation database [92]. All

GO terms with FDR < 0.2 were considered. Semantic similarity between GO terms was

calculated using the Wang method implemented in the `pairwise_termsim` function [93].

The enrichment map was visualized using the `emapplot` function [94] which displays the

significantly enriched terms with at least 2 genes.

Third-party studies

A systematic literature search was performed using PubMed to identify previous studies that

conducted DNA profiling on pure DCIS or DCIS mixed with invasive lesions. The search

strategy included terms related to "ductal carcinoma in situ", "genetic markers", "DCIS

prognosis", "DCIS progression", "DCIS to IDC", "dcis dna", "dcis prognosis dna markers", "copy

number alterations", and "somatic mutations". Studies were included if they reported genomic

analyses of DCIS samples using sequencing or copy number profiling techniques and were

published within the last 10 years. Twelve studies met the inclusion criteria, and their key

findings were summarized in **Supplementary Table 1**. The review emphasized genetic

alterations and pathway dysregulation that may drive DCIS initiation and progression to

invasive disease.

<u>Declarations</u>

Ethics approval and consent to participate

Research ethics board approval was obtained from Sunnybrook Health Sciences Centre,

Toronto, Ontario (#2738). This study was facilitated through ICES which is named as a

prescribed entity in section 45 of PHIPA (Regulation 329/04, section 18) which allows access

and utilization of administrative data for research purposes with a waived requirement for

consent.

Consent for publication

Not Applicable

Availability of data and materials

The dataset analyzed in this study is not publicly available due the personal, sensitive, and

inherently identifying nature of raw genomic data. Access to raw data and patient metadata

may be provided but is controlled and requires institutional material data transfer agreements

(contact person: eileen.rakovitch@sunnybrook.ca).

The scripts used to reproduce the analyses performed in this study are available in the

Dumeaux Lab GitHub Repository https://github.com/dumeaux-lab/dcis-dna_paper.

Competing Interests

The authors declare no competing interests.

Funding

This work was supported by Canadian Institute for Health Research (CIHR) project grant

#391682. We thank the Canadian Foundation for Innovation J. Evans Leaders Fund grant

#43481 for the support of the computing infrastructure used throughout our analyses.

ER holds LC Campbell Chair for breast cancer research. NR received Breast Cancer Canada

and Ontario Graduate Scholarships.

We thank Genome Quebec Innovation Center for RNA processing and sequencing.

Data Acknowledgement

This study was supported by ICES, which is funded by an annual grant from the Ontario

Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). The opinions, results

and conclusions reported in this paper are those of the authors and are independent from the

funding sources. No endorsement by ICES, the MOH or MLTC is intended or should be inferred.

As a prescribed entity under Ontario's privacy legislation, ICES is authorized to collect and use

health care data for the purposes of health system analysis, evaluation and decision support.

Secure access to these data is governed by policies and procedures that are approved by the

Information and Privacy Commissioner of Ontario.

Authors' Contributions

791   Conceptualization, S.N.M, L.P., E.R., M.T.H and V.D.; Methodology, N.R, E.S, V.D.; Investigation,

792   N.R., E.S., M.Z., V.D.; Software N.R., E.J.M., V.D.; Writing – Original Draft, N.R. and V.D.; Writing

793   – Review & Editing, E.S., M.Z., E.J.M., E.H., S.N.M., S.T., L.P., M.T.H. and E.R. ; Funding

794   Acquisition, E.R., M.T.H, E.H., S.N.M, S.T., L.P. and V.D.; Resources, E.R., S.N.M, S.T., L.P. ;

795   Supervision, V.D.

References

1. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast
cancer. Nat Rev Dis Primer. 2019;5:1–31.

2. Sørum R, Hofvind S, Skaane P, Haldorsen T. Trends in incidence of ductal carcinoma in situ:
The effect of a population-based screening programme. The Breast. 2010;19:499–505.

3. Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, et al. The
contribution of mammography screening to breast cancer incidence trends in the United
States: an updated age-period-cohort model. Cancer Epidemiol Biomark Prev Publ Am Assoc
Cancer Res Cosponsored Am Soc Prev Oncol. 2015;24:905–12.

4. Force UPST, Nicholson WK, Silverstein M, Wong JB, Barry MJ, Chelmow D, et al. Screening
for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA.
2024;331:1918–30.

5. Tomlinson-Hansen S, Khan M, Cassaro S. Breast Ductal Carcinoma in Situ. StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 16]. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK567766/

6. Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and
opportunities. Front Med. 2018;12:361–73.

7. Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, et al. Unresected
screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2
study. Breast Edinb Scotl. 2022;61:145–55.

8. Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, et al. Refined estimates of
local recurrence risks by DCIS score adjusting for clinicopathological features: a combined
analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat.
2018;169:359–69.

9. Andor N, Maley CC, Ji HP. Genomic instability in cancer: Teetering on the limit of tolerance.
Cancer Res. 2017;77:2179–85.

10. Trinh A, Gil Del Alcazar CR, Shukla SA, Chin K, Chang YH, Thibault G, et al. Genomic
Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the
Immune System. Mol Cancer Res. 2021;19:623–35.

11. Lin C-Y, Vennam S, Purington N, Lin E, Varma S, Han S, et al. Genomic landscape of ductal
carcinoma in situ and association with progression. Breast Cancer Res Treat. 2019;178:307–
16.

12. Hernandez L, Wilkerson PM, Lambros MB, Campion-Flora A, Rodrigues DN, Gauthier A, et
al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent
invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J
Pathol. 2012;227:42–52.

13. Nagasawa S, Kuze Y, Maeda I, Kojima Y, Motoyoshi A, Onishi T, et al. Genomic profiling
reveals heterogeneous populations of ductal carcinoma in situ of the breast. Commun Biol.
2021;4:1–13.

14. Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, et al. The breast pre-
cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in
situ. Npj Breast Cancer. 2022;8:1–13.

15. Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, et al. A Molecular Portrait of High-Grade
Ductal Carcinoma *In Situ*. Cancer Res. 2015;75:3980–90.

16. Kaplan HG, Dowdell AK, Berry AB, Shimol RB, Robinson FL, Carney CA, et al. Multi-omic
profiling of simultaneous ductal carcinoma in situ and invasive breast cancer. Breast Cancer
Res Treat. 2024;205:451–64.

17. Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, et al. Atypical ductal hyperplasia is a
multipotent precursor of breast carcinoma. J Pathol. 2019;path.5262.

18. Kim SY, Jung S-H, Kim MS, Baek I-P, Lee SH, Kim T-M, et al. Genomic differences between
pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast
cancer. Oncotarget. 2015;6:7597–607.

19. Pareja F, Brown DN, Lee JY, Da Cruz Paula A, Selenica P, Bi R, et al. Whole-Exome
Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma *In Situ* to
Invasive Ductal Carcinoma. Clin Cancer Res. 2020;1078-0432.CCR-19–2563.

20. Strand SH, Rivero-Gutiérrez B, Houlahan KE, Seoane JA, King LM, Risom T, et al. Molecular
classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis
of TBCRC 038 and RAHBT cohorts. Cancer Cell [Internet]. 2022 [cited 2022 Dec 7]; Available
from: https://www.sciencedirect.com/science/article/pii/S1535610822005128

21. Cooper DN, Mort M, Stenson PD, Ball EV, Chuzhanova NA. Methylation-mediated
deamination of 5-methylcytosine appears to give rise to mutations causing human inherited
disease in CpNpG trinucleotides, as well as in CpG dinucleotides. Hum Genomics. 2010;4:406–
10.

22. Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, et al. Clock-like
mutational processes in human somatic cells. Nat Genet. 2015;47:1402–7.

23. Steiert TA, Parra G, Gut M, Arnold N, Trotta J-R, Tonda R, et al. A critical spotlight on the
paradigms of FFPE-DNA sequencing. Nucleic Acids Res. 2023;51:7143–62.

24. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al.
Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

25. Guo Q, Lakatos E, Bakir IA, Curtius K, Graham TA, Mustonen V. The mutational signatures
of formalin fixation on the human genome [Internet]. bioRxiv; 2021 [cited 2024 Dec 6]. p.
2021.03.11.434918. Available from:
https://www.biorxiv.org/content/10.1101/2021.03.11.434918v1

26. Martincorena I, Raine KM, Gerstung M, Dawson KJ, Haase K, Loo PV, et al. Universal

Patterns of Selection in Cancer and Somatic Tissues. Cell. 2017;171:1029-1041.e21.

27. Yuan T, Cantley L. PI3K pathway alterations in cancer: variations on a theme. Oncogene.
2008;27:5497–510.

28. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and
translation. Nat Rev Cancer. 2005;5:921–9.

29. Yang XH, Huang S. PFM1 (PRDM4), a new member of the PR-domain family, maps to a
tumor suppressor locus on human chromosome 12q23-q24.1. Genomics. 1999;61:319–25.

30. Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumorigenesis. J Cell Commun
Signal. 2009;3:255–73.

31. Vecchione A, Fassan M, Anesti V, Morrione A, Goldoni S, Baldassarre G, et al. MITOSTATIN,
a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and
breast cancer. Oncogene. 2009;28:257–69.

32. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger E-M, et al.
Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast
Cancer Res Treat. 2007;103:283–91.

33. Kittiniyom K, Gorse KM, Dalbegue F, Lichy JH, Taubenberger JK, Newsham IF. Allelic loss
on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer
progression. Breast Cancer Res. 2001;3:192–8.

34. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two
overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13
region in human carcinomas. Oncogene. 1992;7:355–61.

35. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13
Amplification in Breast Cancer. Breast Cancer Res Treat. 2003;78:323–35.

36. Houle AA, Gibling H, Lamaze FC, Edgington HA, Soave D, Fave M-J, et al. Aberrant PRDM9
expression impacts the pan-cancer genomic landscape. Genome Res. 2018;28:1611–20.

37. Kader T, Zethoven M, Mahale S, Saunders H, Tjoeka L, Lehmann R, et al. Predictive
biomarkers of breast ductal carcinoma in situ may underestimate the risk of recurrence due to
de novo ipsilateral breast carcinoma development [Internet]. bioRxiv; 2024 [cited 2025 Jan 3].
p. 2024.05.19.594731. Available from:
https://www.biorxiv.org/content/10.1101/2024.05.19.594731v1

38. Ang DC, Warrick AL, Shilling A, Beadling C, Corless CL, Troxell ML. Frequent
phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Mod Pathol.
2014;27:740–50.

39. Silwal-Pandit L, Langerød A, Børresen-Dale A-L. TP53 Mutations in Breast and Ovarian

Cancer. Cold Spring Harb Perspect Med. 2017;7:a026252.

40. Pang J-MB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, et al. Breast ductal
carcinoma in situ carry mutational driver events representative of invasive breast cancer. Mod
Pathol. 2017;30:952–63.

41. Lesurf R, Aure MR, Mørk HH, Vitelli V, Lundgren S, Børresen-Dale A-L, et al. Molecular
Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast
Cancer. Cell Rep. 2016;16:1166–79.

42. Bergholtz H, Lien TG, Swanson DM, Frigessi A, Daidone MG, Tost J, et al. Contrasting DCIS
and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions. NPJ Breast
Cancer. 2020;6:26.

43. Emery LA, Tripathi A, King C, Kavanah M, Mendez J, Stone MD, et al. Early Dysregulation of
Cell Adhesion and Extracellular Matrix Pathways in Breast Cancer Progression. Am J Pathol.
2009;175:1292–302.

44. Glukhova MA, Streuli CH. How integrins control breast biology. Curr Opin Cell Biol.
2013;25:633–41.

45. Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, et al.
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may
influence risk of breast cancer. PLoS Biol. 2011;9:e1001199.

46. Qin X, Strand SH, Lee MR, Saraswathibhatla A, van IJzendoorn DGP, Zhu C, et al. Single Cell
Expression Analysis of Ductal Carcinoma in Situ Identifies Complex Genotypic-Phenotypic
Relationships Altering Epithelial Composition. Cancer Res [Internet]. 2025 [cited 2025 Apr 21];
Available from: https://doi.org/10.1158/0008-5472.CAN-24-3023

47. Deng Y, Chen G, Xiao J, Deng H. Role and potential therapeutic strategies of matrix
mechanics for optimizing tumor radiotherapy. Mechanobiol Med. 2024;2:100037.

48. Prakash J, Shaked Y. The Interplay between Extracellular Matrix Remodeling and Cancer
Therapeutics. Cancer Discov. 2024;14:1375–88.

49. Frascogna C, Mottareale R, La Verde G, Arrichiello C, Muto P, Netti PA, et al. Role of the
mechanical microenvironment on CD-44 expression of breast adenocarcinoma in response to
radiotherapy. Sci Rep. 2024;14:391.

50. Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, et al. Can we
select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes
analysis. Breast Cancer Res Treat. 2013;138:581–90.

51. Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, et al. A
population-based validation study of the DCIS Score predicting recurrence risk in individuals
treated by breast-conserving surgery alone. Breast Cancer Res Treat. 2015;152:389–98.

52. Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Baehner FL, Miller DP, et al. Multigene
Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma
in Situ. J Natl Cancer Inst. 2017;109:djw256.

53. Paszat L, Sutradhar R, Zhou L, Nofech-Mozes S, Rakovitch E. Including the Ductal
Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for
Recurrence After Excision of DCIS. Clin Breast Cancer. 2019;19:35–46.

54. Klein J, Kong I, Paszat L, Nofech-Mozes S, Hanna W, Thiruchelvam D, et al. Close or
positive resection margins are not associated with an increased risk of chest wall recurrence
in women with DCIS treated by mastectomy: a population-based analysis. SpringerPlus.
2015;4:335.

55. Lalani N, Paszat L, Sutradhar R, Thiruchelvam D, Nofech-Mozes S, Hanna W, et al. Long-
term outcomes of hypofractionation versus conventional radiation therapy after breast-
conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys.
2014;90:1017–24.

56. Rakovitch E, Parpia S, Koch A, Grimard L, Soliman H, Stevens C, et al. DUCHESS: an
evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with
low/intermediate-risk DCIS. Breast Cancer Res Treat. 2021;188:133–9.

57. Krueger F. FelixKrueger/TrimGalore [Internet]. 2025 [cited 2025 Jun 2]. Available from:
https://github.com/FelixKrueger/TrimGalore

58. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
universal RNA-seq aligner. Bioinforma Oxf Engl. 2013;29:15–21.

59. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for
alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47.

60. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol.
2010;11:R106.

61. Gendoo DMA, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, et al. Genefu: an
R/Bioconductor package for computation of gene expression-based signatures in breast
cancer. Bioinforma Oxf Engl. 2016;32:1097–9.

62. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised Risk
Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2009;27:1160–7.

63. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence
data. Bioinforma Oxf Engl. 2014;30:2114–20.

64. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
[Internet]. arXiv.org. 2013 [cited 2024 Apr 8]. Available from:
https://arxiv.org/abs/1303.3997v2

65. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of
SAMtools and BCFtools. GigaScience. 2021;10:giab008.

66. Sahraeian SME, Liu R, Lau B, Podesta K, Mohiyuddin M, Lam HYK. Deep convolutional
neural networks for accurate somatic mutation detection. Nat Commun. 2019;10:1041.

67. Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, Lichtenstein L. Calling Somatic SNVs
and Indels with Mutect2 [Internet]. 2019 [cited 2024 Apr 8]. Available from:
http://biorxiv.org/lookup/doi/10.1101/861054

68. Fan Y, Xi L, Hughes DST, Zhang J, Zhang J, Futreal PA, et al. MuSE: accounting for tumor
heterogeneity using a sample-specific error model improves sensitivity and specificity in
mutation calling from sequencing data. Genome Biol. 2016;17:178.

69. Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a
novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic
Acids Res. 2016;44:e108.

70. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic
mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res.
2012;22:568–76.

71. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, et al. Strelka2: fast and
accurate calling of germline and somatic variants. Nat Methods. 2018;15:591–4.

72. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper:
identification of somatic point mutations in whole genome sequencing data. Bioinformatics.
2012;28:311.

73. Sahraeian SME, Fang LT, Karagiannis K, Moos M, Smith S, Santana-Quintero L, et al.
Achieving robust somatic mutation detection with deep learning models derived from
reference data sets of a cancer sample. Genome Biol. 2022;23:12.

74. Barbitoff YA, Abasov R, Tvorogova VE, Glotov AS, Predeus AV. Systematic benchmark of
state-of-the-art variant calling pipelines identifies major factors affecting accuracy of coding
sequence variant discovery. BMC Genomics. 2022;23:155.

75. de Schaetzen van Brienen L, Larmuseau M, Van der Eecken K, De Ryck F, Robbe P, Schuh A,
et al. Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples.
BMC Med Genomics. 2020;13:94.

76. Olson ND, Wagner J, Dwarshuis N, Miga KH, Sedlazeck FJ, Salit M, et al. Variant calling and
benchmarking in an era of complete human genome sequences. Nat Rev Genet. 2023;24:464–
83.

77. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant
Effect Predictor. Genome Biol. 2016;17:122.

78. Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C, Wasserman WW. FLAGS,
frequently mutated genes in public exomes. BMC Med Genomics. 2014;7:64.

79. Alfieri F, Caravagna G, Schaefer MH. Cancer genomes tolerate deleterious coding
mutations through somatic copy number amplifications of wild-type regions. Nat Commun.
2023;14:3594.

80. Mayakonda A, Lin D-C, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and
comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747–56.

81. Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-
wide analysis of mutational processes. Genome Med. 2018;10:33.

82. Raivo Kolde. pheatmap: Pretty Heatmaps [Internet]. 2010 [cited 2025 May 20]. p. 1.0.12.
Available from: https://CRAN.R-project.org/package=pheatmap

83. Martincorena I. im3sanger/dndscv [Internet]. 2025 [cited 2025 May 20]. Available from:
https://github.com/im3sanger/dndscv

84. Mutation data transcript annotation [Internet]. [cited 2025 May 20]. Available from:
https://docs.cbioportal.org/mutation-data-transcript-annotation/

85. Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al.
Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov. 2018;8:174–83.

86. Suehnholz SP, Nissan MH, Zhang H, Kundra R, Nandakumar S, Lu C, et al. Quantifying the
Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discov.
2024;14:49–65.

87. Lesluyes T, Tarabichi M, Haase K, Demeulemeester J, Loo P. Robust and platform-
independent CNA calling with ASCAT v3. 2023.

88. Renault V, Tost J, Pichon F, Wang-Renault S-F, Letouzé E, Imbeaud S, et al. aCNViewer:
Comprehensive genome-wide visualization of absolute copy number and copy neutral
variations. PloS One. 2017;12:e0189334.

89. Franch-Expósito S, Bassaganyas L, Vila-Casadesús M, Hernández-Illán E, Esteban-Fabró R,
Díaz-Gay M, et al. CNApp, a tool for the quantification of copy number alterations and
integrative analysis revealing clinical implications. Robles-Espinoza CD, Cheah KSE, editors.
eLife. 2020;9:e50267.

90. Heinze G, Ploner M, Jiricka L, Steiner G. coxphf: Cox Regression with Firth's Penalized
Likelihood [Internet]. 2023 [cited 2025 May 20]. Available from: https://cran.r-
project.org/web/packages/coxphf/index.html

91. Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R Package for Comparing Biological
Themes Among Gene Clusters. OMICS J Integr Biol. 2012;16:284–7.

92. org.Hs.eg.db [Internet]. Bioconductor. [cited 2025 May 20]. Available from:
http://bioconductor.org/packages/org.Hs.eg.db/

93. pairwise_termsim: pairwise_termsim in enrichplot: Visualization of Functional Enrichment
Result [Internet]. [cited 2025 May 20]. Available from:
https://rdrr.io/bioc/enrichplot/man/pairwise_termsim.html

94. emapplot function - RDocumentation [Internet]. [cited 2025 May 20]. Available from:
https://www.rdocumentation.org/packages/enrichplot/versions/1.13.1.994/topics/emapplot